129 related articles for article (PubMed ID: 34597221)
1. Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist.
Rao S; Smith DA; Guler E; Kikano EG; Rajdev MA; Yoest JM; Ramaiya NH; Tirumani SH
Radiographics; 2021 Oct; 41(6):1839-1856. PubMed ID: 34597221
[TBL] [Abstract][Full Text] [Related]
2. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
Dewan R; Dewan A; Jindal M; Bhardawaj M
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Bendifallah S; Body G; Daraï E; Ouldamer L
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
[TBL] [Abstract][Full Text] [Related]
5. Borderline ovarian tumors: French guidelines from the CNGOF. Part 1. Epidemiology, biopathology, imaging and biomarkers.
Huchon C; Bourdel N; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101965. PubMed ID: 33160106
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of epithelial ovarian cancer subtypes by use of imaging and clinical data: a detailed analysis.
Tanaka YO; Okada S; Satoh T; Matsumoto K; Oki A; Saida T; Yoshikawa H; Minami M
Cancer Imaging; 2016 Feb; 16():3. PubMed ID: 26873307
[TBL] [Abstract][Full Text] [Related]
7. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
[TBL] [Abstract][Full Text] [Related]
8. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
[TBL] [Abstract][Full Text] [Related]
9. Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF).
Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():492-501. PubMed ID: 33262005
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
[No Abstract] [Full Text] [Related]
11. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
[TBL] [Abstract][Full Text] [Related]
13. Multimodality Imaging Approach to Ovarian Neoplasms with Pathologic Correlation.
Taylor EC; Irshaid L; Mathur M
Radiographics; 2021; 41(1):289-315. PubMed ID: 33186060
[TBL] [Abstract][Full Text] [Related]
14. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
15. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
[TBL] [Abstract][Full Text] [Related]
16. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.
Paek J; Lee SH; Yim GW; Lee M; Kim YJ; Nam EJ; Kim SW; Kim YT
Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):338-42. PubMed ID: 21683503
[TBL] [Abstract][Full Text] [Related]
18. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer.
Manganaro L; Michienzi S; Vinci V; Falzarano R; Saldari M; Granato T; Viggiani V; Frati L; Anastasi E
Oncol Rep; 2013 Nov; 30(5):2481-7. PubMed ID: 23970060
[TBL] [Abstract][Full Text] [Related]
19. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors.
McCluggage WG; Young RH
Semin Diagn Pathol; 2005 Feb; 22(1):3-32. PubMed ID: 16512597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
